Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data; and offers clinical research services. It also develops novel treatment options in specific indication areas; focuses in the areas of medical technology to develop innovative methods for diagnosing illnesses and/or patient monitoring; and deploys artificial intelligence to improve diagnostic methods and/or processes in the field of biotechnology. Xlife Sciences AG was founded in 2019 and is headquartered in Zurich, Switzerland.
Frequently asked questions
What sector does Xlife Sciences AG (XLS) operate in?
Xlife Sciences AG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Xlife Sciences AG (XLS) current stock price?
As of the latest data, Xlife Sciences AG stock price is CHF 15.40, with a previous close of CHF 16.00. Xlife Sciences AG lost -CHF 0.60 in the last trading session, representing a -3.75% loss.
What is Xlife Sciences AG (XLS) current market capitalization?
Xlife Sciences AG market cap is approximately 88.82 million.
What is Xlife Sciences AG (XLS) Earnings Per Share (EPS)?
The trailing EPS is -CHF 3.76, and the forward EPS is -CHF 2.94.
Does Xlife Sciences AG (XLS) pay dividends?
No. Xlife Sciences AG does not pay a dividend.
What is Xlife Sciences AG (XLS) beta (volatility) score?
Xlife Sciences AG has a beta of 0.442, indicating lower volatility than the overall market.
